Plasma fibrinogen leaks across the compromised BBB and undergoes coagulation cascade activation and cross-linking by factor XIII. Fibrin(ogen) deposition in the brain parenchyma triggers neuroinflammation via microglial CD18 integrin activation, while D-dimers (fibrin degradation products) enter systemic circulation. Elevated plasma D-dimer thus serves as a functional readout of BBB leakage with coagulation cascade activation—a vascular contribution biomarker distinct from purely neuronal markers like neurofilament light chain. D-dimer testing is widely standardized and clinically available, facilitating rapid validation.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["BBB Breakdown"] -->|"leakage"| B["Plasma fibrinogen leakage"]
B -->|"cascade activation"| C["Coagulation cascade activation"]
C -->|"cross-linking"| D["FXIII cross-linking"]
D -->|"deposition"| E["Fibrin deposition in brain"]
E -->|"integrin binding"| F["Microglial CD18 activation"]
F -->|"pro-inflammatory"| G["Neuroinflammation"]
G -->|"cytotoxic"| H["Neuronal loss and cognitive decline"]
E -->|"degradation"| I["Fibrinolysis and D-dimer elevation"]
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMIDValidation: 0%4 supporting / 3 opposing
✓For(4)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
2
MECH 5CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Fibrinogen leakage into AD brain drives microglial…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: BBB Permeability Biomarkers for Neurodegeneration
Hypothesis 1: Soluble PDGFRβ as a Peripheral Pericyte Degeneration Marker
Title: Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration
Description: Pericyte degeneration is among the earliest events in Alzheimer's disease (AD) and vascular dementia, preceding amyloid deposition and cognitive symptoms. Damaged pericytes release the ectodomain of platelet-derived growth factor receptor β (sPDGFRβ) into the bloodstream, making it a peripheral indicator o
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: BBB Permeability Biomarkers for Neurodegeneration
I will systematically evaluate each hypothesis for mechanistic plausibility, specificity, technical feasibility, and potential confounds. Where applicable, I will identify issues that span multiple hypotheses.
Hypothesis 1: Soluble PDGFRβ (Original: 0.82)
Specific Weaknesses
Non-CNS sources of sPDGFRβ: PDGFRβ is expressed on pericytes, vascular smooth muscle cells (VSMCs), cardiac fibroblasts, hepatic stellate cells, and renal mesangial cells. Systemic inflammatory conditions (atherosclerosis, pul
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Biomarker Utility: HIGH — sPDGFRβ functions as a pharmacodynamic/response biomarker rather than a direct therapeutic target. The underlying PDGFRβ signaling axis, however, represents a legitimate therapeutic target.
Therapeutic Approaches: | Strategy | Agent Class | De
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses": [{"title": "Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration", "description": "Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's dise
If plasma D-dimer elevation specifically reflects fibrinogen leakage through compromised BBB rather than systemic fibrinolysis, then D-dimer levels will correlate with BBB permeability markers (Qalb, sPDGFRβ) and with fibrinogen deposits in brain tissue (postmortem), but not with systemic coagulation parameters (PT, aPTT, platelet count).
pendingconf: 0.50
Expected outcome: In paired plasma/CSF samples (n≥100) with postmortem tissue available, plasma D-dimer correlates with Qalb (r>0.5), sPDGFRβ (r>0.4), and brain parenchymal fibrinogen deposits (IHC score, r>0.4), but shows no correlation with PT, aPTT, or platelet count, distinguishing BBB leakage from systemic coagulation.
Falsified by: Plasma D-dimer correlates with systemic coagulation parameters (PT, aPTT) equally as with BBB markers; brain fibrinogen deposits do not correlate with plasma D-dimer, indicating systemic fibrinolysis dominates plasma D-dimer rather than brain-derived fibrin degradation.
Method: Cross-sectional biomarker study with postmortem validation: plasma D-dimer, Qalb, sPDGFRβ, coagulation panel; brain tissue fibrinogen IHC scoring (n≥40 postmortem cases); correlation and path analysis for fibrinogen leakage vs systemic coagulation contributions.